Brought to you by 
Novartis teams up with Epistem to develop stem cell therapies
05 Mar 2009
Executive Summary
Epistem PLC (using epithelial stem cells to create treatments for various diseases) will combine its stem cell expertise and drug discovery program with Novartis' bioinformatics and disease pathways knowledge to discover and develop new therapeutics across various epithelial conditions reportedly including cancer and gastrointestinal disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis teams up with Epistem to develop stem cell therapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice